On January 31st, ASBM released a fact sheet describing a variety of proposed policy changes at the state and federal level which would weaken the interchangeable biosimilar standard, or circumvent the patient protections it provides. These include new bills and regulations at the federal level, as well as state legislation and proposals which threaten to undermine the hard-won gains of the patient and physician communities to ensure that only interchangeable biosimilars are substituted without physician approval.

Interchangeable Biosimilars: Emerging Policy Challenges

The fact sheet is the third in a series discussing interchangeable biosimilars and related policies. View the others below:

Physician Perspectives on Interchangeable Biosimilars

Interchangeable Biosimilars: Comparing Europe and the U.S.